Core Laboratories Net Worth
Core Laboratories Net Worth Breakdown | CLB |
Core Laboratories Net Worth Analysis
Core Laboratories' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Core Laboratories' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Core Laboratories' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Core Laboratories' net worth analysis. One common approach is to calculate Core Laboratories' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Core Laboratories' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Core Laboratories' net worth. This approach calculates the present value of Core Laboratories' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Core Laboratories' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Core Laboratories' net worth. This involves comparing Core Laboratories' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Core Laboratories' net worth relative to its peers.
Enterprise Value |
|
To determine if Core Laboratories is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Core Laboratories' net worth research are outlined below:
| Core Laboratories generated a negative expected return over the last 90 days | |
| Core Laboratories has high historical volatility and very poor performance | |
| Core Laboratories has a strong financial position based on the latest SEC filings | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| On 27th of May 2025 Core Laboratories paid $ 0.01 per share dividend to its current shareholders | |
| Latest headline from thelincolnianonline.com: Q3 EPS Estimate for Core Laboratories Decreased by Analyst |
Core Laboratories Quarterly Good Will |
|
Core Laboratories uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Core Laboratories NV. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Core Laboratories' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Core Laboratories Target Price Consensus
Core target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Core Laboratories' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Hold |
Most Core analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Core stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Core Laboratories, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCore Laboratories Target Price Projection
Core Laboratories' current and average target prices are 10.95 and 15.80, respectively. The current price of Core Laboratories is the price at which Core Laboratories NV is currently trading. On the other hand, Core Laboratories' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Core Laboratories Market Quote on 29th of May 2025
Target Price
Analyst Consensus On Core Laboratories Target Price
Know Core Laboratories' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Core Laboratories is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Core Laboratories NV backward and forwards among themselves. Core Laboratories' institutional investor refers to the entity that pools money to purchase Core Laboratories' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fred Alger Management, Llc | 2025-03-31 | 736.9 K | Btim Corp | 2025-03-31 | 610.9 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 589.6 K | Northern Trust Corp | 2024-12-31 | 577.8 K | Charles Schwab Investment Management Inc | 2025-03-31 | 498 K | Gendell Jeffrey L | 2025-03-31 | 457 K | Bank Of New York Mellon Corp | 2025-03-31 | 410.4 K | Hotchkis & Wiley Capital Management Llc | 2025-03-31 | 400.8 K | Van Eck Associates Corporation | 2025-03-31 | 395.1 K | Ariel Investments, Llc | 2025-03-31 | 10.3 M | Blackrock Inc | 2025-03-31 | 7.5 M |
Follow Core Laboratories' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 526.5 M.Market Cap |
|
Project Core Laboratories' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.06 | 0.06 | |
| Return On Capital Employed | 0.12 | 0.21 | |
| Return On Assets | 0.05 | 0.10 | |
| Return On Equity | 0.12 | 0.12 |
When accessing Core Laboratories' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Core Laboratories' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Core Laboratories' profitability and make more informed investment decisions.
Please note, the presentation of Core Laboratories' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Core Laboratories' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Core Laboratories' management manipulating its earnings.
Evaluate Core Laboratories' management efficiency
Core Laboratories has Return on Asset of 0.053 % which means that on every $100 spent on assets, it made $0.053 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1157 %, implying that it generated $0.1157 on every 100 dollars invested. Core Laboratories' management efficiency ratios could be used to measure how well Core Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At present, Core Laboratories' Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.1, whereas Return On Tangible Assets are forecasted to decline to 0.06. At present, Core Laboratories' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 25.6 M, whereas Total Assets are forecasted to decline to about 553.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.50 | 5.77 | |
| Tangible Book Value Per Share | 3.24 | 3.40 | |
| Enterprise Value Over EBITDA | 13.28 | 12.56 | |
| Price Book Value Ratio | 3.22 | 6.30 | |
| Enterprise Value Multiple | 13.28 | 12.56 | |
| Price Fair Value | 3.22 | 6.30 | |
| Enterprise Value | 875.5 M | 831.7 M |
The decision-making processes within Core Laboratories are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 1.2837 | Revenue | Quarterly Revenue Growth (0.05) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Core Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on Core Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Core Laboratories insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Core Laboratories Corporate Filings
8K | 27th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 19th of May 2025 Other Reports | ViewVerify | |
| 15th of May 2025 Other Reports | ViewVerify | |
F4 | 5th of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Core Laboratories Earnings Estimation Breakdown
The calculation of Core Laboratories' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Core Laboratories is estimated to be 0.185 with the future projection ranging from a low of 0.17 to a high of 0.2. Please be aware that this consensus of annual earnings estimates for Core Laboratories NV is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.17 Lowest | Expected EPS | 0.20 Highest |
Core Laboratories Earnings Projection Consensus
Suppose the current estimates of Core Laboratories' value are higher than the current market price of the Core Laboratories stock. In this case, investors may conclude that Core Laboratories is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Core Laboratories' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2025 | Current EPS (TTM) | |
| 5 | 92.69% | 0.14 | 0.185 | 0.59 |
Core Laboratories Earnings History
Earnings estimate consensus by Core Laboratories analysts from Wall Street is used by the market to judge Core Laboratories' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Core Laboratories' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Core Laboratories Quarterly Gross Profit |
|
Core Laboratories Earnings per Share Projection vs Actual
Actual Earning per Share of Core Laboratories refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Core Laboratories NV predict the company's earnings will be in the future. The higher the earnings per share of Core Laboratories, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Core Laboratories Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Core Laboratories, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Core Laboratories should always be considered in relation to other companies to make a more educated investment decision.Core Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Core Laboratories' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-04-24 | 2025-03-31 | 0.15 | 0.14 | -0.01 | 6 | ||
2025-01-30 | 2024-12-31 | 0.22 | 0.22 | 0.0 | 0 | ||
2024-10-24 | 2024-09-30 | 0.234 | 0.25 | 0.016 | 6 | ||
2024-07-24 | 2024-06-30 | 0.21 | 0.22 | 0.01 | 4 | ||
2024-04-24 | 2024-03-31 | 0.16 | 0.19 | 0.03 | 18 | ||
2024-01-31 | 2023-12-31 | 0.19 | 0.19 | 0.0 | 0 | ||
2023-11-01 | 2023-09-30 | 0.22 | 0.22 | 0.0 | 0 | ||
2023-07-26 | 2023-06-30 | 0.2 | 0.21 | 0.01 | 5 | ||
2023-04-26 | 2023-03-31 | 0.16 | 0.19 | 0.03 | 18 | ||
2023-02-01 | 2022-12-31 | 0.2 | 0.2 | 0.0 | 0 | ||
2022-10-26 | 2022-09-30 | 0.15 | 0.18 | 0.03 | 20 | ||
2022-07-27 | 2022-06-30 | 0.14 | 0.12 | -0.02 | 14 | ||
2022-04-27 | 2022-03-31 | 0.09 | 0.08 | -0.01 | 11 | ||
2022-02-02 | 2021-12-31 | 0.2 | 0.2 | 0.0 | 0 | ||
2021-10-27 | 2021-09-30 | 0.19 | 0.18 | -0.01 | 5 | ||
2021-07-28 | 2021-06-30 | 0.19 | 0.18 | -0.01 | 5 | ||
2021-04-21 | 2021-03-31 | 0.13 | 0.15 | 0.02 | 15 | ||
2021-01-27 | 2020-12-31 | 0.15 | 0.18 | 0.03 | 20 | ||
2020-10-21 | 2020-09-30 | 0.15 | 0.16 | 0.01 | 6 | ||
2020-07-22 | 2020-06-30 | 0.1 | 0.14 | 0.04 | 40 | ||
2020-04-22 | 2020-03-31 | 0.34 | 0.31 | -0.03 | 8 | ||
2020-01-29 | 2019-12-31 | 0.37 | 0.38 | 0.01 | 2 | ||
2019-10-23 | 2019-09-30 | 0.49 | 0.5 | 0.01 | 2 | ||
2019-07-24 | 2019-06-30 | 0.46 | 0.46 | 0.0 | 0 | ||
2019-04-24 | 2019-03-31 | 0.43 | 0.44 | 0.01 | 2 | ||
2019-01-30 | 2018-12-31 | 0.49 | 0.48 | -0.01 | 2 | ||
2018-10-24 | 2018-09-30 | 0.63 | 0.64 | 0.01 | 1 | ||
2018-07-25 | 2018-06-30 | 0.59 | 0.59 | 0.0 | 0 | ||
2018-04-25 | 2018-03-31 | 0.57 | 0.57 | 0.0 | 0 | ||
2018-01-31 | 2017-12-31 | 0.58 | 0.58 | 0.0 | 0 | ||
2017-10-23 | 2017-09-30 | 0.44 | 0.48 | 0.04 | 9 | ||
2017-07-24 | 2017-06-30 | 0.51 | 0.52 | 0.01 | 1 | ||
2017-04-19 | 2017-03-31 | 0.39 | 0.42 | 0.03 | 7 | ||
2017-01-25 | 2016-12-31 | 0.4 | 0.41 | 0.01 | 2 | ||
2016-10-19 | 2016-09-30 | 0.38 | 0.38 | 0.0 | 0 | ||
2016-07-20 | 2016-06-30 | 0.35 | 0.35 | 0.0 | 0 | ||
2016-04-20 | 2016-03-31 | 0.37 | 0.37 | 0.0 | 0 | ||
2016-01-27 | 2015-12-31 | 0.65 | 0.65 | 0.0 | 0 | ||
2015-10-21 | 2015-09-30 | 0.83 | 0.83 | 0.0 | 0 | ||
2015-07-22 | 2015-06-30 | 0.77 | 0.82 | 0.05 | 6 | ||
2015-04-22 | 2015-03-31 | 0.85 | 0.86 | 0.01 | 1 | ||
2015-01-28 | 2014-12-31 | 1.54 | 1.54 | 0.0 | 0 | ||
2014-10-22 | 2014-09-30 | 1.52 | 1.53 | 0.01 | 0 | ||
2014-07-23 | 2014-06-30 | 1.34 | 1.35 | 0.01 | 0 | ||
2014-04-23 | 2014-03-31 | 1.45 | 1.45 | 0.0 | 0 | ||
2014-01-29 | 2013-12-31 | 1.41 | 1.43 | 0.02 | 1 | ||
2013-10-16 | 2013-09-30 | 1.34 | 1.36 | 0.02 | 1 | ||
2013-07-17 | 2013-06-30 | 1.32 | 1.32 | 0.0 | 0 | ||
2013-04-17 | 2013-03-31 | 1.15 | 1.22 | 0.07 | 6 | ||
2013-01-30 | 2012-12-31 | 1.13 | 1.17 | 0.04 | 3 | ||
2012-10-17 | 2012-09-30 | 1.11 | 1.13 | 0.02 | 1 | ||
2012-07-18 | 2012-06-30 | 1.15 | 1.16 | 0.01 | 0 | ||
2012-04-18 | 2012-03-31 | 1.06 | 1.06 | 0.0 | 0 | ||
2012-02-01 | 2011-12-31 | 1.08 | 1.09 | 0.01 | 0 | ||
2011-10-19 | 2011-09-30 | 0.99 | 1.0 | 0.01 | 1 | ||
2011-07-20 | 2011-06-30 | 0.88 | 0.9 | 0.02 | 2 | ||
2011-04-19 | 2011-03-31 | 0.75 | 0.77 | 0.02 | 2 | ||
2011-02-09 | 2010-12-31 | 0.81 | 0.81 | 0.0 | 0 | ||
2010-10-20 | 2010-09-30 | 0.78 | 0.79 | 0.01 | 1 | ||
2010-07-21 | 2010-06-30 | 0.72 | 0.75 | 0.03 | 4 | ||
2010-04-28 | 2010-03-31 | 0.66 | 0.69 | 0.03 | 4 | ||
2010-02-10 | 2009-12-31 | 0.6 | 0.63 | 0.03 | 5 | ||
2009-10-22 | 2009-09-30 | 0.56 | 0.57 | 0.01 | 1 | ||
2009-07-22 | 2009-06-30 | 0.62 | 0.62 | 0.0 | 0 | ||
2009-04-22 | 2009-03-31 | 0.65 | 0.66 | 0.01 | 1 | ||
2009-02-11 | 2008-12-31 | 0.82 | 0.88 | 0.06 | 7 | ||
2008-10-22 | 2008-09-30 | 0.79 | 0.82 | 0.03 | 3 | ||
2008-07-23 | 2008-06-30 | 0.74 | 0.76 | 0.02 | 2 | ||
2008-04-23 | 2008-03-31 | 0.68 | 0.69 | 0.01 | 1 | ||
2008-02-13 | 2007-12-31 | 0.67 | 0.68 | 0.01 | 1 | ||
2007-10-24 | 2007-09-30 | 0.63 | 0.65 | 0.02 | 3 | ||
2007-07-25 | 2007-06-30 | 0.58 | 0.59 | 0.01 | 1 | ||
2007-04-23 | 2007-03-31 | 0.49 | 0.52 | 0.03 | 6 | ||
2007-02-14 | 2006-12-31 | 0.47 | 0.49 | 0.02 | 4 | ||
2006-10-25 | 2006-09-30 | 0.39 | 0.42 | 0.03 | 7 | ||
2006-07-26 | 2006-06-30 | 0.3 | 0.35 | 0.05 | 16 | ||
2006-04-26 | 2006-03-31 | 0.25 | 0.29 | 0.04 | 16 | ||
2006-02-15 | 2005-12-31 | 0.25 | 0.28 | 0.03 | 12 | ||
2005-10-26 | 2005-09-30 | 0.21 | 0.24 | 0.03 | 14 | ||
2005-07-27 | 2005-06-30 | 0.17 | 0.19 | 0.02 | 11 | ||
2005-04-27 | 2005-03-31 | 0.14 | 0.16 | 0.02 | 14 | ||
2005-02-23 | 2004-12-31 | 0.16 | 0.17 | 0.01 | 6 | ||
2004-10-28 | 2004-09-30 | 0.14 | 0.14 | 0.0 | 0 | ||
2004-07-28 | 2004-06-30 | 0.12 | 0.12 | 0.0 | 0 | ||
2004-04-28 | 2004-03-31 | 0.08 | 0.1 | 0.02 | 25 | ||
2004-02-25 | 2003-12-31 | 0.12 | 0.12 | 0.0 | 0 | ||
2003-10-29 | 2003-09-30 | 0.1 | 0.1 | 0.0 | 0 | ||
2003-07-30 | 2003-06-30 | 0.06 | 0.08 | 0.02 | 33 | ||
2003-05-09 | 2003-03-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2003-02-28 | 2002-12-31 | 0.09 | 0.05 | -0.04 | 44 | ||
2002-10-24 | 2002-09-30 | 0.08 | 0.08 | 0.0 | 0 | ||
2002-07-29 | 2002-06-30 | 0.06 | 0.06 | 0.0 | 0 | ||
2002-05-07 | 2002-03-31 | 0.06 | 0.05 | -0.01 | 16 | ||
2002-02-21 | 2001-12-31 | 0.1 | 0.1 | 0.0 | 0 | ||
2001-10-25 | 2001-09-30 | 0.14 | 0.14 | 0.0 | 0 | ||
2001-07-25 | 2001-06-30 | 0.11 | 0.13 | 0.02 | 18 | ||
2001-04-26 | 2001-03-31 | 0.09 | 0.09 | 0.0 | 0 | ||
2001-02-27 | 2000-12-31 | 0.11 | 0.11 | 0.0 | 0 | ||
2000-10-30 | 2000-09-30 | 0.09 | 0.09 | 0.0 | 0 | ||
2000-07-28 | 2000-06-30 | 0.06 | 0.07 | 0.01 | 16 | ||
2000-04-28 | 2000-03-31 | 0.06 | 0.05 | -0.01 | 16 | ||
2000-02-10 | 1999-12-31 | 0.12 | 0.12 | 0.0 | 0 | ||
1999-10-29 | 1999-09-30 | 0.09 | 0.09 | 0.0 | 0 | ||
1999-07-30 | 1999-06-30 | 0.05 | 0.05 | 0.0 | 0 | ||
1999-04-30 | 1999-03-31 | 0.01 | 0.02 | 0.01 | 100 | ||
1999-03-25 | 1998-12-31 | 0.14 | 0.09 | -0.05 | 35 | ||
1998-10-27 | 1998-09-30 | 0.13 | 0.14 | 0.01 | 7 | ||
1998-07-30 | 1998-06-30 | 0.1 | 0.12 | 0.02 | 20 | ||
1998-04-23 | 1998-03-31 | 0.08 | 0.09 | 0.01 | 12 | ||
1998-02-26 | 1997-12-31 | 0.11 | 0.12 | 0.01 | 9 | ||
1997-10-22 | 1997-09-30 | 0.08 | 0.1 | 0.02 | 25 | ||
1997-08-14 | 1997-06-30 | 0.07 | 0.08 | 0.01 | 14 | ||
1997-04-25 | 1997-03-31 | 0.05 | 0.05 | 0.0 | 0 | ||
1997-02-26 | 1996-12-31 | 0.06 | 0.06 | 0.0 | 0 | ||
1996-10-25 | 1996-09-30 | 0.06 | 0.06 | 0.0 | 0 |
Core Laboratories Corporate Management
| Gwendolyn MBA | Senior Relations | Profile | |
| J Dumas | Vice President Business Development | Profile | |
| Martha Carnes | Presiding Non-Executive Lead Independent Member of the Supervisory Board | Profile | |
| Monique Eeuwijk | Non-Executive Independent Member of the Supervisory Board | Profile | |
| Jacobus Schouten | Managing Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Oil & Gas Equipment & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.896 | Dividend Share 0.04 | Earnings Share 0.59 | Revenue Per Share | Quarterly Revenue Growth (0.05) |
The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.